Our results provide evidence that GBM tumor heterogeneity is maintained by a paracrine signaling circuit involving the IGFBP6-IGF2-IGF-1R axis that abrogates proliferation of TMZ-resistant glioma cells. The gene discussed is IGF1R; the disease is central nervous system cancer.